Stake sale · Healthcare & Life Sciences

Motilal Oswal fund sells 2% of Molbio

By Startup Enthusiast · 1 October 2026

What they do

Molbio Diagnostics is a Goa-based maker of molecular diagnostic tests and devices, now listed on the stock exchanges

A fund managed by Motilal Oswal Alternates sold about 2% of the company for ₹306 crore in open market trades on Wednesday

HDFC Mutual Fund bought roughly 2% at the same price, and the fund had sold a larger block worth ₹394 crore a week earlier

Molbio makes Truenat, a portable machine that runs lab-grade DNA tests (real-time PCR, a method that copies genetic material to detect germs) for infectious diseases such as TB.
It also sells a breast-screening device, a portable X-ray reading tool and digital pathology systems.
Buyers are government health programmes, aid agencies, hospitals and diagnostic labs, mostly in places with few central labs.
It earns by selling the machines and, more importantly, the test kits used with them; most revenue comes from TB kits sold to Indian and overseas public health programmes.
It is used in 90+ countries, with over 8,293 Truenat systems installed in India.
It is based in Verna, Goa, and does research through its subsidiary Bigtec Labs.

Motilal Oswal Alternates (Existing investor) — Sold through its Business Excellence Trust III fund